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A new paradigm in metallobiochemistry describes the activation of inactive metalloenzymes by metal ion
removal. Protein tyrosine phosphatases (PTPs) do not seem to require a metal ion for enzymatic activity.
However, both metal cations and metal anions modulate their enzymatic activity. One binding site is the
phosphate binding site at the catalytic cysteine residue. Oxyanions with structural similarity to phos-
phate, such as vanadate, inhibit the enzyme with nanomolar to micromolar affinities. In addition, zinc
ions (Zn2+) inhibit with picomolar to nanomolar affinities. We mapped the cation binding site close to
the anion binding site and established a specific mechanism of inhibition occurring only in the closed
conformation of the enzyme when the catalytic cysteine is phosphorylated and the catalytic aspartate
moves into the active site. We discuss this dual inhibition by anions and cations here for PTP1B, the most
thoroughly investigated protein tyrosine phosphatase. The significance of the inhibition in phosphoryla-
tion signaling is becoming apparent only from the functions of PTP1B in the biological context of metal
cations as cellular signaling ions. Zinc ion signals complement redox signals but provide a different type
of control and longer lasting inhibition on a biological time scale owing to the specificity and affinity of
zinc ions for coordination environments. Inhibitor design for PTP1B and other PTPs is a major area of
research activity and interest owing to their prominent roles in metabolic regulation in health and dis-
ease, in particular cancer and diabetes. Our results explain the apparent dichotomy of both cations
(Zn2+) and oxyanions such as vanadate inhibiting PTP1B and having insulin-enhancing (‘‘anti-diabetic”)
effects and suggest different approaches, namely targeting PTPs in the cell by affecting their physiological
modulators and considering a metallodrug approach that builds on the knowledge of the insulin-
enhancing effects of both zinc and vanadium compounds.
 2016 The Authors. Published by Elsevier B.V. This is anopenaccess article under the CCBY license (http://
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Over sixty years ago, the late Bert L. Vallee suggested that
‘‘[metal ions] may accelerate or inhibit reactions selectively. With
reference to the latter, one can point out that about 50 percent of
all known enzymes require free sulfhydryl groups for activity: it is
well known that metal ions can react with sulfhydryl groups,
thereby inhibiting these enzymes. It is completely unknown
whether the body avails itself for inhibiting, activating, or both
actions ofmetal – or neither – to control enzyme reactions” [1]. Even
today, it remains largely unknown to which extent the transition
metal ions and zinc control enzymatic reactions. Clearly, metal ions
activate apoenzymes to form active holoenzymes, i.e. metalloen-
zymes, but this aspect ofmetallobiochemistry is not considered part
of regulation. It is estimated that about 50% of all enzymes require a
metal ion, and it is assumed that metalloenzymes are 100% metal-
lated and that the metal ion remains bound during the lifetime of
the protein. However, a paradigm for the opposite situation is
emerging, namely an active apoenzyme without a metal ion and
an inactive holoenzyme with a bound metal ion [2]. This is borne
out by the observation of different types of enzymes with diads or
triads of potentially metal ion-coordinating catalytic groups in the
active site being very tightly inhibited by zinc ions [3,4]. This inhibi-
tion suggestsmetallation states different from 100% occupancy, and
modulation of enzyme activities by fluctuatingmetal ion concentra-
tions. In this article, we will discuss protein tyrosine phosphatases
(PTPs) as metal-modulated enzymes. In contrast to other phos-
phatases, many of which are active metalloenzymes, PTPs are gen-
erally not recognized as metalloenzymes but bind metal cations
such as Zn2+ and metal anions such as vanadate extremely tightly
and with concomitant inhibition. The fact that zinc ion concentra-
tions in the cell are in the range where such enzyme inhibition is
observed strongly supports the idea that zinc(II) modulates protein
tyrosine phosphatase activity in vivo [2]. Physiological metal ion
modulation is different frommetal ion inhibition of PTPs as amech-
anism of toxicity or exploration of metal ligand complexes for phar-
macological regulation.
Zinc(II) is now known to be a cellular signaling ion, but targets
have not been confirmed. PTPs are likely targets as phosphorylation
states of many signaling proteins depend on changes in cellular zinc
(II). It appears that we have missed a major area of metabolic regu-
lation, in particular a role of zinc ions in the most significant way of
signal transduction, namely phosphorylation signaling, and that the
number of enzymes that interact with zinc(II) is significantly larger
than the already impressive estimate that about 3000 human pro-
teins may require zinc(II) as a cofactor [5].
1.1. Protein tyrosine phosphatases (PTPs)
Protein tyrosine phosphorylation is a dynamic process that reg-
ulates many cellular processes through the activities of kinases andphosphatases. Dysregulation of either one of these enzymes is
linked to multiple diseases. The human genome contains 107 PTPs
divided into several subgroups [6]. The cysteine-based PTPs consti-
tute the largest group, which includes the dual-specificity and clas-
sical tyrosine-only transmembrane, receptor-like PTPs (RT-PTP)
and non-transmembrane PTPs [7]. Among the classical non-
transmembrane PTPs is PTP1B (PTPN1), with a catalytic
N-terminal domain, a regulatory region, and a membrane-
localization domain that tethers the enzyme to the cytosolic side
of the endoplasmic reticulum (ER) [8].
PTP1B dephosphorylates several substrates including the insu-
lin and leptin receptors, hence having an important role in metabo-
lism. PTP1B knock-out (KO) mice are more sensitive to insulin and
have lower serum glucose and insulin levels; when put on a high
fat diet, they are resistant to weight gain and insulin. Moreover,
the phosphorylation of the insulin receptor (IR) in both skeletal
muscle and liver is increased in KO compared to control mice [9].
Transgenic mice overexpressing PTP1B specifically in the muscles
show impaired insulin sensitivity [10]. Although mutations of the
PTP1B gene have not been linked to cancer and despite the fact that
PTP1B regulates the activity of both the epidermal growth factor
(EGF) and the platelet-derived growth factor (PDGF) receptors
[11], the enzyme is considered a tumor suppressor. Overexpression
of PTP1B in fibroblasts protects the cells from transformation [12],
and increased PTP1B expression is observed in breast and ovarian
cancer patients, possibly in response to increased levels of tyrosine
phosphorylation [13,14]. However, the actual role or modulation of
PTP1B in cancer treatment or prevention is still under debate.
Owing to these critical cellular functions, PTP1B has been the sub-
ject of numerous investigations.
PTP activity is tightly regulated by a plethora of mechanisms
including oxidation, phosphorylation, sumoylation, and dimeriza-
tion [15–19]. In recent years, evidence accumulated that metal ions
may also regulate PTP activity. Here we review metal ion regula-
tion of PTPs and address its coordination chemistry and signifi-
cance, with a focus on PTP1B.
1.2. The PTP1B-catalyzed reaction
PTP1B is the prototype of protein tyrosine phosphatases, origi-
nally isolated from placenta [20]. The catalytic domain of PTP1B
consists of 280 residues. The enzymatic mechanism responsible
for the dephosphorylation of phosphorylated substrates involves
engagement of the phospho-tyrosine substrate to PTP1B and pro-
motion of a conformational change of the so-called WPD loop that
moves closer to the phospho-tyrosine and allows the side chain of
Asp181 to act as a general acid/base. The side chain of Arg221
changes orientation and assists the closure of the WPD loop.
Interactions between the re-positioned Arg221, which stabilizes
the phosphate group, and the Trp179 and Pro180 residues stabilize
the WDP loop in the closed conformation. The sulfhydryl group
Fig. 1. Protein tyrosine phosphatases catalyze the dephosphorylation of the substrate by a ping-pong mechanism. The enzyme initially is in a resting state with the WPD loop
open (PDB id: 2CM2). Upon substrate (in orange) entry into the catalytic pocket, the WPD loop closes (PDB id: 1PTU, Michaelis complex). The enzyme goes through the first
transition state (PDB id: 3I7Z) and the first product is released with the enzyme left in a phospho-cysteine intermediate (PDB id: 1A5Y, Q262A mutant). A water molecule is
subsequently activated in the second transition state (PDB id: 3I80), before the WPD loop opens again (PDB id: 2HNQ, Michaelis complex) and the inorganic phosphate is
released. Modified from Brandao et al., [24]; reproduced with permission.
Table 1
Free zinc ion concentrations calculated using MaxChelator and MINEQL+ 4.6 software
and compared to the total zinc ion concentration. The buffer composition (50 mM
Hepes/Na+, 0.1 mM tris-carboxyethylphosphine (TCEP), and 1 mM nitrilotriacetic acid
(NTA)), pH (7.4), temperature (25 C), and ionic strength were taken into account to
calculate the free zinc ion concentrations [28].
Zn2+ (Tot) (lM) [Zn2+]free (M) MaxChelator [Zn2+]free (M) MINEQL+
10 2.66  1011 2.93  1011
30 8.14  1011 8.98  1011
100 2.93  1010 3.22  1010
300 1.13  109 1.24  109
500 2.63  109 2.90  109
600 3.95  109 4.34  109
700 6.15  109 6.72  109
800 1.05  108 1.14  108
900 2.37  108 2.45  108
950 5.01  108 4.45  108
990 2.56  107 8.87  108
1000 1.70  106 1.06  107
72 E. Bellomo et al. / Coordination Chemistry Reviews 327–328 (2016) 70–83of Cys215 is the catalytic residue. It has a characteristically low pKa
of 5.5 [21] and performs a nucleophilic attack on the phosphate
group of the phospho-tyrosine substrate while Asp181 transfers a
proton to the tyrosine oxygen group of the leaving substrate. In
the second step, the resulting phospho-cysteine intermediate is
hydrolyzed. Gln262 aligns a water molecule for the nucleophilic
attack on the phospho-cysteine intermediate while Asp181 now
functions as a general base accepting a proton (Fig. 1). Asp181 is
thought to have a very high pKa of 6.8 [22]; it moves 8 Å when
the WPD loop closes and is thought to be protonated in the closed
conformation [22]. The removal of the phosphate from the cat-
alytic cysteine leads to the re-opening of the WPD loop, terminat-
ing the catalytic cycle [23,24].
1.3. Measuring enzymatic activity in the presence of metal ions
PTP activity is measured with several enzymatic assays; most of
them involve the use of a small molecule or a peptide. Dephospho-
rylation of these substrates can be detected by fluorescence (e.g.,
6,8-Difluoro-4-Methylumbelliferyl Phosphate, DiFMUP), electronic
absorption (e.g., p-nitrophenyl phosphate, pNPP) or radioactivity
(e.g., 32P-labeled phospho-peptides) [25]. Many published experi-
ments are based on an end-point assay. Quenching the reaction
at a given time point and calculating the amount of product formed
does not provide evidence for linear rates and thus important char-
acteristics of the enzymes are missed. Therefore, determining the
activity under steady-state conditions with initial rates is superior
for mechanistic investigations. If metal ion binding is competitive
with substrate binding, then IC50 values relative to the substrate
concentration employed in the assays are obtained. The true Ki val-
ues can be significantly lower. For example, an IC50 value of 98 pM
was estimated for receptor protein tyrosine phosphatase b
(PTPRB), but the Ki value is actually 21 pM after a full kinetic anal-
ysis was performed [26].When measuring the activity of enzymes in the presence of
metal ions, their concentrations are rarely controlled. If inhibition
by metal ions occurs at very low concentrations, spurious amounts
of metal ions are already present as contaminants in control reac-
tions in the absence of any added metal ions, even when the chem-
icals in all solutions are certified by commercial metal analysis.
Hence, additional metal analyses and the use of a metal ion buffer
to control metal ion concentrations may be necessary for analyzing
inhibition. Another issue is that typical assay conditions for PTPs
involve additional agents that participate in metal ion buffering;
their metal ion binding capacity must be considered. The origin
of the protein is also important. Most PTPs used in research are
recombinant: they are produced by individual investigators or
bought from companies that focus on the preparation of active
enzymes. The proteins usually contain EDTA, glutathione (GSH),
E. Bellomo et al. / Coordination Chemistry Reviews 327–328 (2016) 70–83 73dithiothreitol (DTT), or other metal ion chelating agents that com-
pete with the protein for metal ion binding. The presence of these
agents will influence the free metal ion concentrations. Therefore,
when assays are performed in the absence of a metal ion buffer, the
reported inhibition constants may need to be re-evaluated as the
inhibition is likely to be stronger.
In our experiments, we employ metal ion buffers that control
the free metal ion concentrations. The choice of the chelating agent
as a metal ion buffer depends on the desired buffering range, and
for the measurement of PTPs it is nitrilotriacetic acid (NTA), as it
buffers metal ions such as Zn(II), Cd(II) and Cu(II) in the range
where inhibition is observed. Moreover, we measure the total
amount of metal present in the solutions by ICP-MS. Using soft-
ware such as MaxChelator [27] or MINEQL+ 4.6 (Environmental
Research Software, Hallowell, ME), we then calculate the free metal
ion concentration from the overall composition of the buffer,
including the concentration of metal ion chelators present in the
solution of the protein, and the measured and added concentra-
tions of metal ions [28]. In this way we obtain the free metal ion
concentrations for each of the total metal ion concentrations added
(Table 1). The differences found when comparing the output from
the two software packages is probably due to the different algo-
rithms used and the fact that, while MaxChelator calculates free
metal ion concentrations using only the total metal ion and chela-
tor concentrations, MINEQL+ also takes into account other buffer
components. The free metal ion concentrations are significantly
different from the total metal ion concentrations. In fact, this metal
ion buffering in vitro is not any different from the situation in vivo,
where all metal ions are buffered in specific ranges by proteins and
small molecules.2. Metal ion coordination in PTP1B
Metal ions bind to proteins through interaction with the donors
of amino acid side chains, the ligands. The cellular concentrations
of the different metal ions vary substantially, and for some metal
ions participating in cell signaling, the concentrations fluctuate
and depend on the status of the cell.
The coordination number is governed by the properties of both
the metal ions (e.g., charges, size) and the ligands (e.g., electroneg-
ativity). Coordination numbers have been analyzed by employing
the Cambridge Structural Database [29]. Although most metal ionsTable 2
Amino acids in the metal ion-binding sites of proteins. Frequencies of each amino acid in a
below 4%. Metal ion-binding polypeptides were extracted from the RCSB Protein Data Ban
Amino acid Metal ion
Ca2+ Cd2+ Cu2+
Arg – – –
Asn 10–15%a – –
Asp 35–40%a
36%b
24%b 5%a
Cys – 10%b 10–15%a
Glu 15–20%a
27%b
27%b 5%a
Gln – – –
Gly 5–10%a – –
His – 26%b 65–70%a
Met – – 5–10%a
Ser 5%a – –
Thr 5%a – –
Tyr – – 5%a
a Metal ion-binding sites were defined as residues within 3.5 Å of the metal ion [30].
b Metal ion-binding sites were defined as residues within 2.5 Å of the metal ion [31].have preferences towards a particular coordination number, they
can assume different geometries and have more than one coordi-
nation number. Moreover, metal ions have ligand preferences
(Table 2).
Although the tabulation shows that arginine and glutamine side
chains are not typical ligands for zinc ions and other metal ions,
there are at least 20 established cases where proteins coordinate
zinc ions with glutamine [32].
2.1. Metal ion binding to PTP1B
The enzymatic activity of PTPs is affected by both metal cations
and (metal) oxyanions. Among those, zinc ions (Zn2+) and vanadate
ions (VO43) were originally described as inhibitors of PTP1B [20].
2.2. Metal cations inhibit PTPs
We interrogated the Protein Data Bank (PDB) for metal cations
(Cd(II), Cu(II), Zn(II), Fe(II)) bound to human PTP1B. None of the
129 crystal structures deposited contains any of these metal ions
near the catalytic site. This finding, however, does not mean that
metal ions are unable to bind to PTP1B.
2.2.1. Zinc(II)
Zinc(II) has been known as an inhibitor of PTPs since the early
1980s [33]. Since then, others confirmed inhibition and reported
increasingly higher IC50 or Ki values [28,34]. What is often over-
looked, however, is that, compared to other metal ions such as cad-
mium(II) or copper(II), the inhibition of PTPs by zinc(II) occurs at
biologically relevant metal ion concentrations. PTP1B is not the
only protein tyrosine phosphatase inhibited by zinc ions. Other
PTPs are also inhibited (Table 3).
Zinc ions also inhibit PTPs in cultured cells. When glioma cells
were incubated with zinc ion concentrations in the presence of
the zinc(II) ionophore pyrithione, a time-dependent increase in
protein tyrosine phosphorylation was observed [34,35]. Zinc ions
also activate the epidermal growth factor receptor (EGFR) in
human bronchial epithelial cells. Although the activation fails to
trigger the dimerization of EGFR typically induced by EGF, it
increases phosphorylation, which is accompanied by a loss of PTP
activity. In particular, zinc ions caused an inhibition of PTP1B, sug-
gesting that the mechanism responsible for zinc ion-inducedgiven type of metal ion-binding site are tabulated; where not shown the frequency is
k (PDB).
Fe3+ Mg2+ Mn2+ Zn2+
– – – –
– 5–10%a 5%a –
10–15%a 35–40%a
35%b
40–45%a
37%b
10–15%a
17%b
10–15%a – – 40–45%a
23%b
– 15–20%a
22%b
15–20%a
25%b
10–15%a
15%b
– – – –
– – – –
45–50%a 5%a 20–25%a
26%b
30–35%a
36%b
– – – –
– 5–10%a – –
– 5–10%a – –
5–10%a – – –
Table 3
Zinc(II) inhibition of human protein tyrosine phosphatases.
Protein tyrosine phosphatase Inhibition Reference
PTP1B IC50 = 3–17 nM [28,34]
SHP-1 IC50 = 93 nM [35]
SHP-2 IC50 = 1–2 lM [34]
LAR (PTPRF) IC50 = 20 lM [34]
TC-PTP IC50 = 200 nM [4]
PTPRB IC50 = 98 pM; Ki = 21 pM [26]
PTEN IC50 = 0.6 nM [39]
Table 4
Potential zinc ion-coordinating ligands in three structures of PTP1B as obtained from
molecular docking [28].
PDB id Pose 1a Pose 2 Pose 3 Pose 4 Pose 5
2CM2 Lys141
Thr143
Glu159
Glu161
Glu2
Glu4
Glu6
Glu4
Lys5
Glu8
His0
His1
Glu2
Asp240
Asp29
Pro31
Cys32
Met258
3I80 Lys141
Thr143
Glu159
Glu161
Glu2
Met3
Glu4
Ile275
Ala278
Glu8
Asp11
Asp181
Cys215
Arg221
Gln262
Asp289
Lys292
Glu293
1A5Y Met74
Glu75
Glu76
Asp252
His60
Glu101
Asp181
P-Cys215
Gln266
His25
Glu26
Glu129
Glu132
a Candidate binding modes are referred to as ‘‘poses” in molecular docking.
Fig. 2. Docking simulation performed on different PTP1B crystal structures. (A)
Closed form (PDB id: 3I80) and (B) phospho-cysteine intermediate (PDP id: 1A5Y).
Since the position of the zinc ion in the two structures differs by about 4 Å Gln266
in (A) is too far for coordination. Gln262 is not shown in (B) as the structure was
obtained on a Gln262Ala mutant to avoid hydrolysis of the phospho-cysteine
intermediate. Protein structure is represented in pale cyan, zinc ion as pink sphere,
and relevant amino acids as sticks [28].
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PTP1B by Zn2+ [36–38].
When we examined the inhibition of PTP1B by zinc ions, we
observed that the enzyme remained at least 50% active even in
the presence of high zinc ion concentrations. This observation is
not unique to PTP1B. Both PTPRG and HePTP behave in similar
ways (M. Wilson, MSc thesis, King’s College London). Because the
dephosphorylated substrate is released in the first catalytic step,
the retention of 50% activity suggests that the enzyme is inhibited
in the second catalytic step when it is still in the phosphorylated
form. This observation would indeed explain the failure to see
complete inhibition even at high zinc ion concentrations [28].
We have recently investigated the possible binding sites of zinc
(II) to PTP1B with molecular docking [28]. Since the enzyme under-
goes conformational changes during the catalytic cycle, we investi-
gated zinc(II) binding to three different conformations of the
protein: the enzyme in the open conformation (PDB id: 2CM2),
the enzyme in the closed conformation with the phospho-
cysteine intermediate (PDB id: 1A5Y) and the dephosphorylated
enzyme in the closed conformation, which was obtained by remov-
ing vanadate from the second transition state structure (PDB id:
3I80). For each of the structures, we found several zinc ion-
binding sites at the periphery of the enzyme (Table 4, [28]).
Remarkably, zinc ion binding to the catalytic site was observed
only when the conformational change of the WPD loop has
occurred and the catalytic residue Asp181 has moved into the active
site (PDB id: 1A5Y, pose 3 and PDB id: 3I80, pose 4). In the dephos-
phorylated form of the enzyme (obtained by removing vanadate
from the structure), zinc(II) is in a coordination sphere surrounded
by Asp181, Arg221, Gln262 and Cys215 (Fig. 2A). In the phospho-
intermediate form, phospho-Cys215, Asp181 and Gln266 and Gln262
are all in the inner coordination sphere of zinc(II) (Fig. 2B). The
crystal structure of this form examined has a Gln262Ala mutation,
hence Gln262 coordination of zinc(II) is not shown in Fig. 2B but it
has a critical position for coordination (Fig. 2A). If Gln262 isre-introduced in the position in silico, the coordination of the
docked zinc ion is very strong with a distance of about 1.5 Å. If
Tyr46 changes its position, it may become a ligand as well. The
open conformation fails to accommodate zinc(II) in the catalytic
pocket. The idea that zinc(II) binds to the catalytic site is supported
by the observations that zinc(II) is a competitive inhibitor of PTPRB
[26]. When comparing the two binding modes (Fig. 2A and B), the
center of the zinc ion moves at least 4 Å. The inhibitory effect of
zinc(II) is expected to be twofold. When Gln262 and Asp181 become
ligands of zinc(II) in the closed conformation, Gln262 no longer
aligns a water molecule for catalysis and Asp181 can no longer serve
as the catalytic base for the dephosphorylation of the phospho-
cysteine intermediate in the second step of the reaction. Hence
zinc(II) traps the enzyme in the phospho-cysteine form. The coor-
dination of zinc(II) in this form is exclusively from oxygen donors.
Though the zinc(II) site in the closed conformation of PTP1B is
unlike typical zinc(II) coordination in zinc metalloenzymes, it is
not without precedence. The number of oxygen donors is sufficient
to provide a strong binding site as zinc(II) binds to the magnesium
(II) site in phosphoglucomutase and inhibits the enzyme with pico-
molar affinity [40]. In PTP1B, Gln266 (1 oxygen), Asp181 (1–2), phos-
phate (1–2), and Gln262 (1) could all contribute oxygen ligands. Gln
has been identified as a ligand of zinc(II) in proteins [32].
Table 5
Oxyanions in biological systems.
Name of ion Formulaa Chargea PDB code # entries Geometryb,c
Arsenate HAsO42 2 ART 3 TH
Chromate H2CrO4 1 – 0 –
Molybdate MoO42 2 MOO 22 TH, TB
Phosphate HPO42 2 PO4 4156 TH
Sulfate SO42 2 SO4 14234 TH, TB
Tungstate WO42 2 WO4 48 TH, TB
Vanadate H2VO4 1 VO4 80 TH, TB
a Observed under standard condition of temperature (25 C) and pH (7.4).
b TH – tetrahedral; TB – trigonal bipyramidal.
c From the Protein Data Bank (PDB).
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Hydrogen bonding of metal ion-bound water molecules also makes
an energetic contribution to the stability of metal ion sites in pro-
teins. The implication of zinc(II) locking the enzyme in the phos-
phorylated state is that the site is now no longer accessible for
substrate. We believe that zinc(II) binding in the active site in
the closed conformation in the absence of phosphate (Fig. 2A) is
not relevant as the closed conformation would require the prior
presence of substrate, e.g. the phosphorylated insulin receptor.
Zinc(II) would not be an insulin-mimetic as the insulin receptor
would not function in signaling if PTP were to remain bound to
it. We cannot rule out, however, that zinc(II) locks the enzyme in
a closed conformation once the second substrate, i.e. the phosphate
group, has left the catalytic site. At present, there does not seem to
be a precedent for this mechanism as the cleavage of the phospho-
cysteine intermediate is coupled to the transition of the enzyme
from the closed to the open conformation.2.2.2. Iron(II)
Mononuclear di-citrate (cit) iron complexes interact with PTPs
and inhibit their activities [41]. Specifically, while Fe:cit prepared
with Fe(III) in 1:1 and 1:2 ratios did not inhibit tyrosine phos-
phatases, inhibition was observed for the 1:4 and the 1:10 Fe:cit
preparations (at concentrations between 250 and 500 lM of the
complex) [41]. Fe2+ inactivates recombinant PTPs (PTP1B, CD45,
and LAR) in a concentration-dependent manner [42]. Since reactive
oxygen species are implicated in regulating PTP1B activity, and
iron(II) is involved in the Fenton reaction (decomposing H2O2),
the interaction of H2O2 and Fe2+ with PTP1B was also examined.
Physiological concentrations of Fe2+ (500 nM, [43]) not only inac-
tivated the enzyme less than H2O2 but also prevented its inactiva-
tion by H2O2, possibly by generating hydroxyl radicals which,
although oxidizing, are unspecific reactants likely unable to reach
the catalytic site of PTPs because they would not diffuse that far
in vivo. Fe2+ also inhibits the dual specificity protein phosphatase
VHR and the inhibition was reversible by addition of EDTA, sug-
gesting a direct binding of iron(II) to this PTP [44].2.2.3. Copper(II)
Inhibition of PTPs has been explored with copper(II) complexes.
The inhibition constants vary between low nM to low lM values
[45–48]. The effect of the free metal ion, though unbuffered, was
also examined for both PTP1B and the dual specificity protein
phosphatase VHR. Copper(II) strongly inhibited with IC50 values
of 100 nM and 1 lM for VHR and PTP1B, respectively. However,
enzymatic activity was not fully recovered by adding EDTA. Only
the presence of reducing agents reactivated the enzymes com-
pletely, suggesting that copper(II) oxidizes the catalytic cysteine
[44]. Considering the very low free cytosolic copper ion concentra-
tions and the fact that intracellular copper is mostly in the reduced
state (copper(I)), these experiments are not physiologically signif-
icant. When investigating PTP1B in the presence of increasing con-
centrations of Cu2+ and a metal buffering system, we found a much
lower IC50 value of 0.3 pM (unpublished data, K. Birla Singh).2.2.4. Cadmium(II)
Although Cd2+ inhibits other phosphatases, there is no report on
its effect on PTPs [49]. When PTP1B was investigated in the pres-
ence of increasing concentrations of Cd2+ in an NTA-containing
buffer, an apparent inhibition constant of 5 nM was obtained
(unpublished data, K. Birla Singh), very similar to the one for zinc
(II) (5.6 nM), based on concentrations of free cadmium ions
calculated as indicated above for zinc.2.3. Oxyanions inhibit PTP activity
Inorganic phosphate is the hydrolytic product of the PTP reac-
tion. It is a competitive inhibitor of PTP1B with a Ki value of
17 mM [50]. Other oxyanions with structural similarities to the
phosphate group inhibit PTPs with different affinities: molybdate,
arsenate [50], tungstate and vanadate. When analyzing the inhibi-
tion of PTP1B under our experimental conditions, apparent Ki (IC50)
values of 1.5 lM (vanadate), 9 lM (heptamolybdate), 210 lM
(tungstate), 200 lM (arsenate), and 54 mM (nitrate) were mea-
sured (unpublished data, K. Birla Singh). The different inhibition
constants may reflect the different ionization states of the anion
at the pH of investigation, the propensity of vanadate to form a
covalent intermediate analogous to the phospho-intermediate in
contrast to the other anions, which form Michaelis-like complexes,
and geometric factors, such as in the case of nitrate, which has a
planar geometry (Table 5).
2.3.1. Vanadate(V) and oxidovanadium(IV)
The bioinorganic coordination chemistry of vanadium is dis-
cussed in a number of very recent reviews, covering vanadate in
structural biology [51], the reaction dynamics of vanadium ions
[52], binding, transport, and storage of vanadium in cells [53],
vanadium in medicine [54,55], and vanadium as inhibitors of phos-
phatases [56]. Vanadate has structural similarities with phosphate,
and was therefore suggested to be a transition state analog of
phosphate in phosphatases [57]. However, the two anions differ
significantly in their acid/base and redox chemistries. The pKa2 val-
ues are 7.8 for dihydrogen vanadate (H2VO4) and 7.2 for dihydro-
gen phosphate. Thus there is comparatively less di-anion (HVO42)
at pH 7.0. Only the oxidation state +5 of the non-metal phospho-
rous is relevant for mammalian biology, whereas minimally two
oxidation states of the metal vanadium, +4 and +5, are important.
Thus phosphorous is redox-inert whereas vanadium is redox-
active in biology. Vanadate was discovered as a strong inhibitor
of (Na/K)-ATPase in a commercial ATP preparation (Ki = 40 nM in
the presence of 25 mMMg2+) [58]. It is a competitive inhibitor of
PTP1B with a Ki of 0.38 ± 0.02 lM (pH 7.3) [59]. In contrast to other
oxyanions such as sulfate, vanadate, like phosphate, forms a cova-
lent intermediate with the enzyme. Vanadate inhibits bovine low
molecular weight PTP competitively with a Ki of 1.0 ± 0.6 lM (pH
7.5) and forms a trigonal bipyramidal (tbp) SN2 transition state
[60]. While a square planar geometry of the 5-coordinate com-
plexes of vanadate is preferred in solution, the geometry of inter-
mediates is tbp in a large number of phosphatases [56,61].
Analysis of geometry was based on angular parameters using
s-values, the ratio of the angle of the axial vs the equatorial ligands
in tbp geometry divided by 60, i.e., s = (b  a)/60, which, for an
ideal geometry with b = 180 and a = 60, gives a s-value of 1
[62]. In the covalent intermediate of PTP1B, the sulfur donor of
the catalytic cysteine becomes the fifth ligand of vanadium(V) with
a rather long bond distance (2.4–2.5 Å in the two transition states)
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with s-values ranging from 0.83 (PDB id: 3I7Z) to 0.90 (PDB id:
3I80) and structures described best as umbrella-like inversions
with deviations of ligands from the equatorial plane in exploded
transition states, a term referring to increased bond lengths of
the breaking and forming bonds. Further investigations employing
shape analysis – continuous symmetry measures [63] – demon-
strated that the umbrella-like distortions of the tpb species are
on a pathway from and to the tetrahedral anions [64]. These char-
acteristics make vanadate a transition state analog for PTPs [65].
Vanadate and other oxyanions that form product complexes like
phosphate have been used for 3D-structural elucidation of the
enzymatic mechanism of PTP1B. The structures of two transition
states of PTP1B with vanadate ions were analyzed crystallograph-
ically [24]. The structures share close structural characteristics
with the metaphosphate and orthophosphate transition states in
phosphate transfer reactions [65]. The first transition state was
obtained by crystallizing PTP1B in the presence of metavanadate
and a peptide, while the second transition state was obtained by
incubating PTP1B crystals with the peptide and orthovanadate. In
both transition states, vanadate binds to the sulfur of Cys215; the
equatorial oxygen atoms bind to the amide groups of the P-loop
(Ser216, Ala217, Gly218 and Ile219) and to the guanidinium group of
Arg221. Gln262 in the first transition state is rotated compared to
the position in the second transition state, where it binds the apicalFig. 3. X-ray crystal structure of (A) first transition state complex between PTP1B,
metavanadate, and the Tyr in the peptide DADEYL (PDB id: 3I7Z) and (B) second
transition state complex between PTP1B and orthovanadate (PDB id: 3I80) [24].
Protein structure is represented in pale cyan, peptide DADEYL in orange, and
vanadate and relevant amino acids as sticks. H-bonds are depicted as yellow dot
lines.oxygen in the trigonal vanadate moiety [24] (Fig. 3A and B). The
motion of Gln262 is critically important as it aligns a water mole-
cule as a nucleophile for releasing the second product, phosphate,
from the intermediate. Together the structures of complexes with
different oxyanions, i.e., phosphate, vanadate, and tungstate were
instrumental in formulating the reaction pathway of PTP1B (Fig. 1).
Pervanadate, which contains monoperoxo or diperoxo ligand
bridges in the equatorial position, also inhibits PTPs and is a more
potent insulin-mimetic than vanadate [66]. However, the mecha-
nism of inhibition is different from vanadate. Pervanadate is an
irreversible inhibitor of PTPs. Mass spectrometric analyses
revealed that addition of pervanadate to the enzyme resulted in
the oxidation of the catalytic cysteine to a sulfonic acid derivative
[59].
Crystals of the Yersinia enterocolitica PTP YopH, in which the Trp
in the WPD loop had been mutated to a Phe, grown in the presence
of vanadate, showed electron density that was interpreted as a
divanadate (V2O7x) ion bound in the active site [67]. This particu-
lar species of vanadate has never been observed in wild type
Yersinia PTP or in any other PTP. A 2.2 Å structure with vanadate
is deposited in the PDB (id: 2I42) and is discussed as having a
mononuclear VO4S covalent intermediate [56]. Although vanadate
forms oligomers in solution, wild type, active PTPs are expected to
catalyze the decomposition of dimeric forms in solution with the
same mechanism used for phospho-peptide substrates [68]. The
lengths of the V–S and V–O bonds were similar to those observed
in the structures of PTP and monomeric vanadate; the second
vanadium atom is coordinated in a distorted trigonal bipyramid
with two bridging oxygens. The other three oxygens bind to the
NH atoms of Gln446 and Gln450, to a water molecule, and to the
amino group of Lys447 (Fig. 4). The structure with divanadate is
intriguing as it demonstrates that indeed two metal ions can be
accommodated in the active site of a PTP.
Vanadate undergoes multiple chemical reactions, such as com-
plexation with many commonly employed buffers, reduction, and
olation to form polyoxymetallates [69–71]. Because of this com-
plex chemistry, it is important to determine the species interacting
with proteins at physiological pH. For example, H2VO4, the main
species at pH 7, can increase its coordination number by binding
additional water molecules or dimerize to divanadate, tetravana-
date, or species of higher nuclearity, in particular at higher concen-
trations. In order to minimize oligomerization, it is recommended
to prepare stock solutions of vanadate >0.1 mM at pH 10 and boil
the solution [72]. Compounds with thiols such as glutathione andFig. 4. X-ray crystal structure of Yersinia enterocolitica PTP (R235C, W354F)
complexed with divanadate (PDB id: 3F9B) [67]. Protein structure is represented
in pale green, and vanadate and relevant amino acids as sticks. H-bonds are
depicted as yellow dot lines.
Fig. 5. X-ray crystal structures of (A) Yersinia PTP (R235C) (PDB id: 1YTW) [79] and
(B) human PTP1B (PDB id: 2HNQ) complexed with tungstate [80]. Protein structures
are represented in pink and pale cyan respectively, tungstate and relevant amino
acids as sticks. H-bonds are depicted as yellow dot lines, distances are in Å.
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tion was investigated in the cytoplasm of human erythrocytes after
uptake of vanadate and advanced to explain the inability of exoge-
nously added vanadate to inhibit the (Na/K)-ATPase in vivo [73].
The reduction of vanadate(V) to vanadium(IV) species may also
be important in the presence of thiol-based reducing agents typi-
cally employed in assays of PTPs. Whether vanadate is an oxidant
for the catalytic cysteine in PTP1B has not been considered and/or
examined, however. The best known salt of V(IV) is vanadyl sulfate,
which contains the oxidovanadium (‘‘vanadyl”) cation [V(IV)O]2+.
This cation is also an inhibitor of PTP1B with a Ki value of
0.11 lM (pH 7.0, 37 C) [74]. It must be kept in mind, however, that
upon dissolution of vanadyl sulfate a significant fraction of vana-
dium(IV) oxidizes immediately to vanadium(V) at neutral pH.
Quite appropriately, it was discussed how an anion as well as a
cation can be an inhibitor of phosphatases [71]. The answer lies
in the speciation of the cation. The vanadyl cation is stable at acidic
pH and the hydrated species [VO(H2O)5]2+ with a square pyramidal
geometry undergoes consecutive hydrolysis when the pH increases
to form anionic species at nanomolar to submicromolar concentra-
tions: [VO(H2O)4(OH)], [(VO)2(OH)5], and [VO(OH)3]. Thus,
there are anionic and cationic species in equilibriumwith insoluble
{VO(OH)2}n and with [(VO)2(OH)5] being a prominent species at
neutral pH [71]. In addition, vanadium(V) also exists in both catio-
nic and anionic forms [75]. In acidic solutions, the cationic species
is [V(V)O2]+, which binds to proteins such as transferrin [75]. Coor-
dination of vanadium(IV) and vanadium(V) ions with biological
ligands is another factor of speciation in a biological matrix [70].
In addition to inorganic vanadate(V) and oxidovanadium(IV),
many organic vanadium(V) and vanadium(IV) compounds were
investigated as inhibitors of PTP1B owing to their potential as
antidiabetic agents and for many other therapeutic indications
(see below). Vanadium complexes inhibit PTP1B with IC50 values
between 30 nM and about 1 lM but rarely do they show pro-
nounced selectivity for a particular phosphatase [76]. The actual
mechanism of inhibition remains to be elucidated. So far, only
vanadate has been investigated in 3D structures of PTPs. The ratio-
nale for the significant activity in synthesizing metallodrugs as
inhibitors of PTPs is based on the expectation that membrane per-
meability, compartmentalization, toxicity, and selectivity for dif-
ferent PTPs can be achieved by the organic ligand, thus
overcoming the inherent poor selectivity of vanadate.
Vanadium compounds receive a great deal of interest as antidi-
abetic agents and, more recently, as potential anticancer drugs
[55,69]. Because of their favorable properties (membrane perme-
ability, stability, and potency), work focused on organic chelates
of VO2+, oxidovanadium(IV). VO(acac)2 (acac = acetylacetonate) is
an uncompetitive inhibitor of PTP1B when assayed with a phos-
photyrosine peptide that stimulates the epidermal growth factor
receptor (EGFR) [77]. Likewise, bis-(maltolato)oxovanadium(IV)
(BMOV) is a reversible inhibitor of glutathione transferase-tagged
PTP1B with an IC50 of 0.86 ± 0.02 lM. In this case, the inhibition
is mixed with Ki values of 1.2 and 2.1 lM for the enzyme and the
enzyme/substrate (p-nitrophenyl phosphate) complex, respec-
tively [78].
2.3.2. Tungstate
The crystal structure of Yersinia PTP (YopH) with tungstate indi-
cates that tungstate behaves like other phosphate mimetics,
namely closing the WPD loop [79] (Fig. 5A). In contrast to vana-
date, tungstate does not form a covalent intermediate. PTP1B has
also been crystallized with tungstate [80] (Fig. 5B). Two of the
tungstate oxygens form hydrogen bonds with the amide groups
of Ser216, Ile219 and Gly220. Arg221 also coordinates with one of
the tungstate oxygens. Tungstate binding to the catalytic site of
PTP1B causes conformational changes in the enzymes: the sidechains of both Cys215 and Arg221 re-position towards the oxyanion.
However, the WPD loop remains in the open conformation. The
fact that the crystals were obtained by soaking PTP1B in the pres-
ence of high concentrations of tungstate together with the fact that
the WPD loop is closed in the Yersinia PTP structure, suggests that
binding of tungstate in the open conformation of PTP1B is an arti-
fact of the crystallization condition.
2.3.3. Molybdate
There are no available structures of PTP1B with molybdate.
There is, however, a structure of the bovine low molecular weight
PTP co-crystallized with molybdate [60]. In this work, the phos-
phatase was crystallized with tungstate, molybdate and vanadate
and the inhibition constants of the metal oxyanions were mea-
sured. Vanadate was the stronger inhibitor, displaying typical tbp
geometry, while molybdate and tungstate were weaker inhibitors
(9 lM and 210 lM, respectively). Unlike vanadate, but similar to
tungstate in PTP1B, molybdate does not form a covalent intermedi-
ate but in this case the enzyme is in the closed conformation
(Fig. 6).
2.3.4. Nitrate
Other oxyanions also interact with PTP1B. No information is
available on the effect that nitrate (NO3) has on PTP activity.
Hence we determined its inhibition. The IC50 value is 54 mM
(unpublished data, K. Birla Singh). Crystal structures of PTP1B in
Fig. 6. X-ray crystal structure of bovine low molecular weight PTP complexed with
molybdate (PDB id: 1Z13) [60]. Protein structure is represented in green, molybdate
and relevant amino acids as sticks. H-bonds are depicted as yellow dot lines,
distances are in Å.
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captured in both an open and a closed conformation
(Fig. 7A and B). Nitrate is held in place by non-covalent interac-
tions: in the closed form, it forms hydrogen bonds with Arg221,
Asp181, Ser216, Ala217, and Gly220 (Fig. 7B); in the open form, the dis-
tances to Ala217, Gly220 and Arg221 are slightly less and it also forms
hydrogen bonds with Ile219 (Fig. 7A). The movement of the WPD
loop seems to change only slightly the position of the oxyanion
in relation to the catalytic site [81]. Nitrate was also crystallized
in a complex with Yersinia PTP [79]. In this case, the WPD loop is
in the closed conformation and the coordination is virtually identi-
cal to the one observed in PTP1B (Fig. 7C).2.3.5. Arsenate
Arsenate inhibits PTP1B with a Ki of 4.3 mM [50]. Under our
experimental conditions the IC50 value is 200 lM (unpublished
data, K. Birla Singh). There is no crystal structure of PTP1B with
arsenate. However, arsenate reductase belongs structurally to the
family of PTPs and several crystal structures have been solved
[82]. Remarkably, the protein phosphatase CD45 belonging to the
PTP superfamily reduces arsenate [83].Fig. 7. X-ray crystal structure of human PTP1B complexed with nitrate (PDB id: 4BJO): (A
and nitrate and relevant amino acids as sticks. H-bonds are depicted as yellow dot lines, d
nitrate (PDB id: 1YTN) [79]. Protein structure is represented in pink, nitrate and relevant3. Significance of PTP1B inhibition
Both metal cations and oxyanions inhibit the activity of PTP1B.
Although several metal ion complexes have been investigated with
regard to inhibiting PTPs and shown promises as metallodrugs, and
in the case of vanadium compounds entered clinical trials, none
have developed into human therapeuticals. Given the inhibition
of PTP1B by free metal ions, investigations of the interaction of
metal ion complexes with PTPs need to consider the stability of
the metal ion complexes in order to determine whether the inhibi-
tion is due to the metal ion complex itself or the cation dissociating
from the complex. Understanding the interaction of free metal ions
and/or oxyanions with PTP1B, therefore, is important in order to
improve the design of potential therapeutic agents.
Investigation of vanadate as an insulin-mimetic dates back to
1899, when it was observed that oral administration of Na3VO4
to diabetic patients decreased glycosuria [84]. The study did not
have any follow up until 80 years later, when it was shown that
several inorganic vanadium compounds affected adipocytes simi-
lar to insulin, namely stimulating glucose transport and oxidation,
and hepatocytes, namely increasing glycogen synthesis and
inhibiting gluconeogenesis [85]. Notably, this work was per-
formed at a time when the search for a molecular function of
vanadium in biology was on-going, a scientific journey that
started when very high (hundreds of millimolar) concentrations
of vanadium were found in tunicates (ascidians) [86]. While vana-
dium is now well established as an essential element in nitroge-
nases and haloperoxidases in some branches of life, an essential
molecular function in humans remains unknown. Inhibition of
PTP1B by vanadate provides one explanation of the insulin-like
effects of vanadate, often referred to as ‘‘insulin-mimetic” but
more appropriately described as insulin-enhancing or insulin
sparing, though other PTPs involved in the insulin signal trans-
duction pathways may contribute as well [87]. Numerous studies
have explored the various insulin-enhancing effects of vanadate
and vanadium compounds both in vitro and in vivo. Of interest
was the discovery that Na3VO4 normalized hyperglycemia in an
animal model of diabetes [88], suggesting that vanadate or vana-
dium compounds could potentially be used for the treatment of
diabetes [89]. Speciation again is an issue as vanadate and vana-
dium(V) compounds are thought to be reduced to vanadium(IV)
compounds in cells and will form complexes with other metabo-
lites. Moreover, in the presence of reactive species such as under
conditions of peroxide signaling, there is the possibility of oxida-) open form and (B) closed form [81]. Protein structure is represented in pale cyan,
istances are in Å. (C) X-ray crystal structure of Yersinia PTP (R235C) complexed with
amino acids as sticks. H-bonds are depicted as yellow dot lines, distances are in Å.
Table 6
Intracellular free metal ion concentrations ([Me2+]i).
Metal Free [Me2+]i Reference
Zn 600 pM–1 nM [112,113]
Fe <5 lM [114,115]
Cu 1 aM [116]
Ca 100 nM [117]
Mg 1 mM [118,119]
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1-electron redox cycling, thus accounting for the formation of
organic radicals and the toxicity of vanadium compounds. Among
vanadium compounds, bis(ethylmaltolato)oxidovanadium(IV)
(BEOV), showed encouraging results and was in clinical trials as
a prodrug for the treatment of type 2 diabetes [90]. This vanadyl
(VO2+, oxidovanadium(IV)) chelate and the corresponding acety-
lacetonate have been investigated in detail structurally and with
regard to their synergism with insulin in cells [91]. Phase I and
phase II pre-clinical trials were performed with organic vanadium
compounds as antidiabetic drugs (while vanadyl sulfate and
vanadate, owing to the fact that their toxicity was known, went
directly into phase II clinical trials) but had to be discontinued
because of renal complications [90,92,93]. So far, vanadium com-
pounds join the failures of finding specific drugs that target
PTP1B, which after enormous efforts were deemed ‘‘undruggable”
by the pharmaceutical industry. However, PTP1B has received
additional attention because it is a validated therapeutic target
in Her2-positive breast cancer and inhibitors are discussed as a
therapeutic approach to Rett syndrome and anxiety disorders
[94,95].
Similar to vanadate, tungstate alters glucose metabolism when
added to rat hepatocytes [96]. Follow-up experiments confirmed
that administration of tungstate, like vanadate, to diabetic rats nor-
malized glycaemia and hepatic glucose metabolism [97]. Sodium
tungstate has been proposed as a potential therapeutic agent for
type 2 diabetes and although its effects as an inhibitor of PTP1B
have been acknowledged, the antidiabetic properties of sodium
tungstate may be related to effects other than that of being a PTP1B
inhibitor [98]. Similar conclusions were reached when the role of
tungstate as an antiplatelet agent was investigated and the effects
were thought to be due to inhibition of PTP1B – at least in part
[99].
Molybdate has also been widely used as a PTP inhibitor
[100–102]. In contrast to vanadium and tungsten, molybdenum
is an essential element for humans. Its function as a cofactor in
enzymes is linked to its binding to the pterin prosthetic group. In
rat hepatocytes, molybdate inhibits glycogen synthase and
increases fructose bisphosphate, while it increases glucose uptake
in rat adipocytes [103]. The action is likely due to an increased
phosphorylation of the insulin receptor and the insulin receptor
substrate [104]. Experiments with molybdenum supplementation
have also been performed on diabetic rats. Molybdate decreased
hyperglycemia and glycosuria, improved glucose tolerance, and
replenished glycogen stores [105].
It is unclear whether the concentrations at which vanadate and
other oxyanions inhibit the activity of PTP1B occur under physio-
logical conditions. Relatively low metal oxyanions concentrations
(e.g. vanadate, 1 lM) inhibit PTPs. Vanadium concentrations in
human blood are 0.2–15 nM (median 50 ng/L in 108 human sub-
jects) [106]. Based on about 1 mg of vanadium in a 70 kg human
and assuming a random distribution, one can calculate an average
vanadium concentration of 0.3 lM [54]. Other (non-metal) oxyan-
ions, such as phosphate, nitrate, borate, sulfate inhibit in the mil-
limolar range, but none of the inhibition of these ions appears to
be physiologically relevant in living cells. For example, phosphate
inhibits with a Ki of 17 mM while the cellular phosphate concen-
trations are in the range of 0.5–5 mM.
Zinc ions, on the other hand, are physiologically important
inhibitors of enzymes [2]. Other metal ions, either essential
metal ions such as iron(II,III) and copper(I,II) or non-essential
metal ions have pathophysiological/toxicological effects on PTPs.
In order to interpret metal ion inhibition of PTPs, an understand-
ing of the cellular concentrations of total and free metal ions is
necessary.3.1. Physiological metal cation concentrations
Apart from the properties of the metal cation and its affinity for
ligands, the actual concentration of the metal ions available for
protein binding is a crucial factor in determining whether or not
a protein indeed binds a particular metal ion in the cell. The factor
determining the availability is the range in which metal ions are
buffered in the cell. Cellular metal homeostasis is a well-
controlled process, involving many transporter proteins as well
as storage in organelles.
In general, the affinity of a divalent metal ion for a set of ligands
follows the Irving-Williams series [107], which ranks the metal ion
complexes based on their stability in the following order:
Mg2þ <Mn2þ < Fe2þ < Co2þ < Ni2þ < Cu2þ > Zn2þ
This signifies that metal ions such as Zn2+ or Cu2+ form the most
stable complexes with a particular set of ligands. However, by
increasing the total concentration of a weaker binding metal
cation, the cell can enhance its competitiveness for a target protein
if the buffering allows for an increased availability.
The cytosolic free concentrations of essential metal ions vary
over many orders of magnitude and they are kept in defined ranges
by buffering in order to avoid overlapping functions of the different
metal ions (Table 6). Although the concentration of some metal
ions is low at steady state, there are instances where it increases
either globally or locally. For instance, the cytosolic Ca2+ concentra-
tion increases in response to second messengers such as inositol
trisphosphate, IP3 [108]. Zinc ion concentrations also increase in
response to various stimuli such as high glucose concentrations,
insulin, growth factors, and changes to a lower reducing potential
[109–111].3.1.1. Zinc(II)
Zinc ions have been referred to as insulin-mimetics as incuba-
tion of cells with zinc ions results in glucose transport [120] and
lipogenesis [121]. The insulin-mimetic effects are associated with
an increased tyrosine phosphorylation, and it has been suggested
that these effects are due to a direct interaction of zinc ions with
PTPs [35]. There is a large body of evidence suggesting that zinc
ions are indeed bona fide endogenous modulators of PTPs, putting
the observation of zinc ion inhibition observed in vitro in a physi-
ological context. Some PTPs such as PTPRB could be inhibited at
resting zinc ion concentrations [26], while others will need
increased cytosolic zinc ion concentrations as the inhibition con-
stants are above the cytosolic free zinc ion concentrations
(Table 3).
Cellular zinc ion homeostasis is tightly controlled. It is fairly
well established now that the concentration of free zinc ions in
the cytosol is in the range of a few hundred pM [112,113]. The con-
centration of zinc ions inside intracellular organelles, however, is
more controversial and investigations using different fluorescent
probes provided very different values [122,123]. Metallothionein
is a major zinc ion-binding protein contributing to maintaining
the cytosolic free zinc ion concentrations at high picomolar/low
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porters also participate in this control. Fourteen members of
importers (Zip/SLC39A) and at least nine out of the ten members
of transporters (ZnT/SLC30A) transport zinc ions into or out of the
cytosol [125]. These proteins are located on the plasma membrane
as well as on membranes of intracellular organelles. The release of
zinc ions into the cytosol through some of these transporters
results in free zinc ion concentrations that are locally higher than
those under steady-state conditions. Stimuli such as prolonged
hyperglycemia [109], EGF [111] or insulin [110] increase the cellu-
lar free zinc ion concentration. Two pathways may be relevant for
local increases of zinc ions at the endoplasmic reticulum (ER)
where PTP1B resides. One pathway is the transport of zinc ions
through zinc transporters (Fig. 8). Zip7 (SLC39A7) is located on
the ER membrane and responsible for transporting zinc ions into
the cytosol. Stimulation of cells with EGF in the presence of high
intracellular Ca2+ activates casein kinase 2 (CK2) that is conse-
quently recruited to the ER, where it phosphorylates Zip7 on
Ser275 and Ser276 [111]. This modification causes an opening of
the channel and increases in zinc ion concentrations in the cytosol.
However, because zinc ions are buffered in the cytosol, the global
free zinc concentration would not be expected to change. The con-
centration of zinc at the ER membrane would be high enough for
PTP1B inhibition. Insulin increases cellular free zinc ion concentra-
tions. For example, treatment of a T-cell lymphoma cell line with
5–10 lg/mL insulin elicits a 2–3.5-fold increase of zinc ion concen-
trations [110]. To rule out that the increase of intracellular zinc
ions in these experiments was due to an influx of zinc contained
in the insulin preparation, which often contains rather high con-
centrations of zinc ions, the same experiment was repeated after
boiling the insulin sample and hence denaturing the hormone.
No increase in fluorescence was observed with this preparation
[110].
Increases of cellular free zinc ions can also arise from the pro-
duction of reactive oxygen species (ROS) and oxidation of metal-
lothioneins (MTs) (Fig. 8). Insulin binding and activation of the
insulin receptor induces an increase of intracellular H2O2 in bothFig. 8. Mechanisms involved in increasing cytosolic zinc after insulin stimulation.
Insulin binding to its receptor induces zinc increase through the zinc transporter
Zip7 located on the endoplasmic reticulum (ER) membrane or through other Zips
located on the plasma membrane. Insulin stimulates the insulin receptor (IR), which
triggers an increase in ROS production. Oxidation of metallothioneins (MT) releases
the bound zinc ions. Zinc then inhibits PTP1B, hence blocking the dephosphory-
lation of the insulin receptor. The figure was made using Servier Medical Art (www.
servier.com).hepatocytes and adipocytes [126]. ROS are produced from Nox4,
the phagocytic NAD(P)H oxidase catalytic subunit, which is highly
expressed in insulin-sensitive adipocytes. Expression of dominant
negative forms attenuated insulin-stimulated H2O2 production in
adipocytes while silencing of Nox4 inhibited the insulin signaling
cascade [127]. Targets of H2O2 are PTPs, in particular PTP1B, which
is reversibly inhibited, thus enhancing insulin signaling pathways
[128] (Section 3.2). A second mode of action is the reaction of
H2O2 with MTs. Oxidation of MTs results in release of tightly bound
zinc ions, which also inhibit PTP1B [129,130]. Insulin stimulation
therefore enhances its own signal through inhibition of PTP1B by
redox and zinc ion signals (Fig. 8). Incubation of adipocytes in a
medium containing high glucose concentrations resulted in
enhanced H2O2 production and PTP oxidation [131]. Incubation
of cells with high glucose concentrations also has been linked with
an increase in intracellular free zinc ion concentrations [109],
demonstrating the joint action of redox and zinc signals on modu-
lation of PTP activity. However, the mode of inhibition by zinc ions
suggests that modulation of PTP1B activity by either oxidation or
zinc ions occurs at two distinct stages. PTP1B is oxidized at the
resting level, independently of physiological stimulation and sub-
strate binding. In contrast, zinc ions modulate PTP1B after physio-
logical stimulation and substrate binding. Aside from the fact that
zinc ion signals can be a product of oxidative signaling, zinc ion sig-
nals are specific based on affinities of zinc ions for coordination
environments and can provide a longer lasting inhibition of PTPs
[132].
3.1.2. Other metal ions
The inhibition of PTP1B by metal ions other than zinc ions does
not appear to be physiologically significant but it may have signif-
icance under conditions where tissues and cells are exposed to
toxic metal ion concentrations [37].
3.2. Redox regulation of PTP1B
Oxidation/reduction (redox) is a key regulatory event in PTP
function. Intracellular signals resulting in the production of ROS
increase tyrosine phosphorylation due to inhibition of PTPs [133].
ROS oxidize the active site cysteine (Cys215 in PTP1B) and abrogate
its nucleophilic function. Oxidation is reversible as the sulfenic acid
form of the oxidized cysteine reacts with the adjacent serine side
chain (Ser216) to form a cyclic sulfenamide with the purpose of
avoiding further oxidation and facilitating reduction to restore
the active PTP [134] (Fig. 9). Formation of the cyclic sulfenamideFig. 9. Redox chemistry of the active site cysteine in PTPs.
Fig. 10. Modulation of PTP1B by oxidation of the catalytic cysteine and zinc binding at different stages of the catalytic cycle. While oxidation targets the enzyme in the open
conformation, zinc modulates the enzyme after the WPD loop has closed. Modified from Brandao et al. [24].
E. Bellomo et al. / Coordination Chemistry Reviews 327–328 (2016) 70–83 81is accompanied by conformational changes as the PTP loop with
the signature motif VHCxAGxxRSG and Tyr46 (in PTP1B), normally
buried in the structure, become more solvent-exposed.
Oxidation can also lead to the formation of sulfinic or sulfonic
acid derivatives of Cys215 [7,134]. The oxidation to sulfonic acid
is irreversible. Additional modifications are glutathionylation,
sulfenation with hydrogen sulfide and reactions with reactive sele-
nium compounds. The reduction of the oxidized cysteine depends
on an interaction of the protein with thioredoxin [135,136].3.3. PTP1B as a drug target
Given the role of PTP1B in the pathogenesis of type 2 diabetes
and its involvement in cancer signaling, immense research efforts
are made to pharmacologically targeting the enzyme [137].
Antisense-based oligonucleotides designed to downregulate PTP1B
expression and normalizing glycaemia and improving insulin sen-
sitivity have entered Phase II clinical trials [138,139]. Although the
trial is over, the results are not yet available to the public [140].
There are two main challenges when designing PTP inhibitors:
cell membrane permeability and selectivity [137]. Inhibitors for
PTPs, and in particular PTP1B, include phosphate mimetics, such
as vanadium compounds. Chelation overcomes the issues of cell
membrane permeability, and a barrier of positive charges around
the active site. Selectivity continues to be an issue as many PTPs
share common residues in their catalytic sites.
Since diabetes and other diseases are associated with changes
in zinc status, one would assume that an approach targeting intra-
cellular control of zinc is worth exploring for pharmacological
intervention.4. Conclusions
Phosphatases are the jockeys while kinases are the racehorses
in cellular regulation. Phosphatases perform the task of regulating
phosphorylation signaling and they are regulated themselves. We
demonstrate additional principles of the regulation of PTPs, namely
reversible inhibition by metal cations that inhibit differently from
metal anions such as vanadate. Oxyanions bind to the enzymes inthe open conformation but cations inhibit only if an oxyanion such
as phosphate (or vanadate) is already present and new interactions
for cation binding are made possible in the closed conformation of
the protein when the catalytic aspartate moves into the active site.
Metal cation inhibition modulates PTPs differently from estab-
lished redox modulation. Metal cations bind when phosphate (or
another oxyanion) blocks the cysteine in the phospho-
intermediate, and thus the sulfur is no longer available for redox
modification. Possibly, the combined anion/cation inhibition pro-
tects the enzyme from redox modification.
Metal modulation has been ignored in virtually all discussions
of the biology of PTPs. The inhibition of PTPs by metal ions was
recognized when these enzymes were initially characterized [26].
The reasons for a lack of progress are that the structural chemistry
of metal cation inhibition was not explored, and in fact could not
have been explored, because it requires a particular intermediate
of the enzyme in the reaction cycle, and that the relationship
between physiological zinc ion concentrations and inhibition was
not recognized. Oxyanion modulation alone is not important phys-
iologically unless it is seen in the context of metal cation binding.
There is controlled zinc ion release at the ER where PTP1B resides
and it is now understood that physiological concentrations of zinc
ions are commensurate with the inhibition constants of PTPs for
zinc ions.
Transition metal ions are redox active and influence the redox
state of the catalytic cysteine in PTPs. In contrast, zinc(II) is
redox-inert in biology and cannot change the redox state of the
cysteine. However, ROS release zinc ions from metallothionein
and other protein sites and thus increase free zinc ion concentra-
tions. Therefore, some of the effects of ROS on PTPs may be indi-
rect, namely in providing zinc ions as a specific inhibitor of the
enzymes. In as much as redox species are ER localized, so is zinc
ion release, and specific pathways of zinc ion release support the
physiological relevance. The physiological context of dual modula-
tion of PTPs by metal ions and redox is likely another level of con-
trol of these important enzymes (Fig. 10).
The interplay of anions, cations and redox agents provides a
very rich chemistry for affecting the active site of PTPs and conse-
quently their biological control. On a more speculative note, the
zinc ion inhibition of the phosphorylated form relates the activity
82 E. Bellomo et al. / Coordination Chemistry Reviews 327–328 (2016) 70–83of the PTPs to the phosphorylation state of their substrates, i.e.
inhibition occurs during enzymatic turnover while redox modula-
tion targets the free enzyme before (or after) it has been enzymat-
ically active.
Metal ion interactions with PTPs extend the role of metal ions in
phosphatase action and phosphorylation signaling. Alkaline phos-
phatases use a binuclear zinc site and a regulatory magnesium
ion, acid phosphatases a binuclear iron site, and protein phos-
phatases such as calcineurin a mixed binuclear zinc/iron site. Thus,
in addition to using metalloenzymes in the control of phosphoryla-
tion signaling, biology has availed itself to using metal ions such as
zinc and calcium for biological regulation of phosphatases.
It is remarkable that billions of dollars have been spent on drug
design and clinical trials of inhibitors of PTPs without appreciating
these structural and biological principles of regulation. The new
insights provide a different perspective and may give another
impetus for rational drug design and for inhibiting PTPs more
specifically by modulating zinc metabolism in vivo. Such an
approach appears to be attractive since the zinc and vanadium
inhibition of PTP1B provides a mechanistic basis for the rather
copious literature on the pharmacology of insulin-mimetic and
anti-diabetic effects of zinc and vanadium complexes [141–143].Acknowledgments
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